Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

CAMP

Camp4 Therapeutics Corp

Pharmaceutical Preparations · SIC 2834CIK 1736730Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$3.0M
Net Income FY2025
$(80.0M)
EPS (Basic, as reported)
$-2.65
Net Margin FY2025
-2298.5%
ROE FY2025
-168.5%
Total Equity
$48.0M
Shares Out
63M
Business description

Camp4 Therapeutics Corp — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2023–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 3
Fiscal yearFY2023FY2024⚑FY2025
Revenue013
Research & development(41)(39)(38)
General & administrative(12)(15)(17)
Total operating expenses(52)(54)(56)
Operating income(52)(53)(53)
Interest & investment income312
Other income (expense), net31(28)
Income tax expense000
Net income(49)(52)(80)
EPS — basic($124.80)($11.04)($2.65)
EPS — diluted($124.80)($11.04)($2.65)
Shares outstanding — basic (M)0530
Shares outstanding — diluted (M)0530
  • ⚑ Weighted-average shares changed ×6.00 between FY2024 and FY2025 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.